These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 9592394)

  • 1. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis.
    Mielcarek N; Riveau G; Remoué F; Antoine R; Capron A; Locht C
    Nat Biotechnol; 1998 May; 16(5):454-7. PubMed ID: 9592394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis.
    Renauld-Mongénie G; Mielcarek N; Cornette J; Schacht AM; Capron A; Riveau G; Locht C
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7944-9. PubMed ID: 8755582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against intranasal infection of mice with Bordetella pertussis.
    Robinson A; Ashworth LA; Baskerville A; Irons LI
    Dev Biol Stand; 1985; 61():165-72. PubMed ID: 2872102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
    Li R; Lim A; Alonso S
    Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection.
    Alonso S; Pethe K; Mielcarek N; Raze D; Locht C
    Infect Immun; 2001 Oct; 69(10):6038-43. PubMed ID: 11553541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
    Sato H; Sato Y
    Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cellular and acellular anti-pertussis vaccines].
    Locht C
    Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Construction of the genetically attenuated bacteria Bordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form].
    Siniashina LN; Siniashina LS; Semin EG; Amelina IP; Karataev GI
    Mol Gen Mikrobiol Virusol; 2010; (3):31-6. PubMed ID: 20886687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model.
    Marr N; Oliver DC; Laurent V; Poolman J; Denoël P; Fernandez RC
    Vaccine; 2008 Aug; 26(34):4306-11. PubMed ID: 18582518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation.
    Mielcarek N; Debrie AS; Raze D; Quatannens J; Engle J; Goldman WE; Locht C
    Vaccine; 2006 Apr; 24 Suppl 2():S2-54-5. PubMed ID: 16823926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of mutant strains producing pertussis toxin cross reacting materials.
    Sato Y; Sato H; Chazono M; Ginnaga A; Tamura C
    Dev Biol Stand; 1991; 73():93-107. PubMed ID: 1778339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role.
    Alonso S; Reveneau N; Pethe K; Locht C
    Infect Immun; 2002 Aug; 70(8):4142-7. PubMed ID: 12117922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e.
    Li R; Lim A; Ow ST; Phoon MC; Locht C; Chow VT; Alonso S
    Vaccine; 2011 Jul; 29(33):5502-11. PubMed ID: 21624415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin.
    Cahill ES; O'Hagan DT; Illum L; Redhead K
    FEMS Microbiol Lett; 1993 Mar; 107(2-3):211-6. PubMed ID: 8472903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.
    Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C
    Vaccine; 2010 Oct; 28(43):7047-53. PubMed ID: 20708998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.
    Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C
    Vaccine; 2008 Oct; 26(45):5722-7. PubMed ID: 18762220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies produced against a fragment of filamentous haemagglutinin (FHA) of Bordetella pertussis are able to inhibit hemagglutination induced by the whole adhesin.
    Colombi D; Horton DS; Oliveira ML; Sakauchi MA; Ho PL
    FEMS Microbiol Lett; 2004 Nov; 240(1):41-7. PubMed ID: 15500977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
    Novotny P; Chubb AP; Cownley K; Charles IG
    Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model.
    Komatsu E; Yamaguchi F; Eguchi M; Watanabe M
    Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.